Top

Published in:

01-06-2012 | Original Paper

Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram

Authors: J. M. Warwick, P. D. Carey, N. Cassimjee, C. Lochner, S. Hemmings, H. Moolman-Smook, E. Beetge, P. Dupont, D. J. Stein

Published in: Metabolic Brain Disease | Issue 2/2012

Abstract

Social anxiety disorder (SAD) is characterised by fear of social or performance situations where the individual is exposed to unfamiliar people or to possible scrutiny by others. The literature on dopamine ligands and dopamine genotypes in SAD is however inconsistent. In this study we measured the effects of SSRI pharmacotherapy on dopamine transporter (DAT) binding in patients with SAD, also addressing variability in DAT genotype. Adult subjects meeting DSM-IV criteria for generalised SAD were studied before and after 12 weeks of pharmacotherapy with the selective serotonin reuptake inhibitor (SSRI) escitalopram. DAT single photon emission computed tomography (SPECT) using ¹²³I-FP-CIT was performed at baseline, and repeated at 12 weeks. Striatal DAT binding was analysed for changes following therapy, and for correlations with clinical efficacy, in the whole group as well as for a subgroup with the A10/A10 DAT genotype. The study included 14 subjects (9 male, 5 female) with a mean (SD) age of 41 (±13) years. The subjects’ Liebowitz Social Anxiety Scale (LSAS) score was significantly decreased following pharmacotherapy. In the combined group the left caudate and left putamen showed clusters of increased DAT binding after therapy. The left caudate changes were also observed in the subgroup of 9 A10/A10 homozygotes. However no correlation was found between improved symptoms and DAT binding. The changes found in DAT binding in the caudate and putamen may be due to serotonergic activation of dopamine function by SSRI therapy. This is consistent with previous work indicating decreased DAT binding in SAD, and increased DAT binding after SSRI administration.

Adolphs R (2003) Cognitive neuroscience of human social behaviour. Nat Rev Neurosci 4:165–178PubMedCrossRef

American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC

Blum K, Braverman ER, Wu S et al (1997) Association of polymorphisms of dopamine D₂ receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviours (SAB). Mol Psychiatry 2:239–246PubMedCrossRef

Bonhomme N, Esposito E (1998) Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J Clin Psychopharmacol 18:447–454PubMedCrossRef

De Win MM, Habraken JB, Reneman L et al (2005) Validation of ((123)I)beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 30:996–1005PubMedCrossRef

Dewey SL, Smith GS, Logan J et al (1995) Serotonergic modulation of striatal dopamine measured with Positron Emission Tomography (PET) and in vivo microdialysis. J Neurosci 15:821–829PubMed

Esposito E, Di Matteo V, Di Giovanni G (2008) Serotonin–dopamine interaction: an overview. Prog Brain Res 172:3–6PubMedCrossRef

First MB, Spitzer RL, Gibbon M et al (1996) Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV). American Psychiatric Press, Inc, Washington, DC

Fuke S, Suo S, Takahashi N et al (2001) The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 1:152–156PubMedCrossRef

Grant KA, Shively CA, Nader MA et al (1998) Effect of social status on striatal dopamine D₂ receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. Synapse 29:80–83PubMedCrossRef

Heinz A, Goldman D, Jones DW et al (2000) Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22:133–139PubMedCrossRef

Jacobsen LK, Staley JK, Zoghbi SS et al (2000) Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 157:1700–1703PubMedCrossRef

Johnson MR, Lydiard RB, Zealberg JJ et al (1994) Plasma and CSF HVA levels in panic patients with co-morbid social phobia. Biol Psychiatry 36:426–427

Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466–476PubMed

Kennedy JL, Neves-Perreira M, King N et al (2001) Dopamine system genes not linked to social phobia. Psych Genetics 11:213–217CrossRef

Kessler RC, Berglund P, Demler O et al (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:593–602PubMedCrossRef

Kim CH, Cheon KA, Koo MS et al (2007) Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with (¹²³I)IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology 55:156–162PubMedCrossRef

King R, Mefford IN, Wang C et al (1986) CSF dopamine levels correlate with extraversion in depressed patients. Psychiatry Res 19:305–310PubMedCrossRef

Kugaya A, Seneca NM, Snyder SJ et al (2003) Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28:413–420PubMedCrossRef

Laakso A, Vilkman H, Kajander J et al (2000) Prediction of detached personality in healthy subjects by low dopamine transporter binding. Am J Psychiatry 157:290–292PubMedCrossRef

Lader M, Stender K, Burger V et al (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19:241–248PubMedCrossRef

Liebowitz MR (1987) Social phobia. Mod Probl Pharmacopsychiat 22:141–173

Liebowitz MR, Schneier FR, Campeas R et al (1992) Phenelzine vs atenolol in social phobia: a placebo-controlled trial. Arch Gen Psychiatry 49:290–300PubMed

Martinez D, Gerlernter J, Abi-Dargham A et al (2001) The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24:553–560PubMedCrossRef

Mayleben M, Gariepy J, Tancer M et al (1992) Genetic differences in social behaviour: neurobiological mechanisms in a mouse model (abstract). Biol Psychiatry 31S:216A

Mill J, Asherson P, Browes C et al (2002) Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am Med Genet 114:975–979CrossRef

Pallanti S, Quercioli L, Rossi A et al (1999) The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. J Clin Psychiatry 60:819–823PubMedCrossRef

Pirker W, Asenbaum S, Kasper S et al (1995) Beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 100:247–256PubMedCrossRef

Richard IH, Schiffer RB, Kurlan R (1996) Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 8:383–392PubMed

Rorden C, Brett M (2000) Stereotaxic display of brain lesions. Behav Neurol 12:191–200PubMed

Rowe DC, Stever C, Gard JM et al (1998) The relation of the dopamine transporter gene (DAT1) to symptoms of internalising disorders in children. Behav Genet 28:215–225PubMedCrossRef

Ruscio AM, Brown TA, Chiu WT et al (2008) Social fears and social phobia in the USA: results from the national comorbidity survey replication. Psychol Med 38:15–28PubMedCrossRef

Schneier FR, Liebowitz MR, Abi-Dargham A et al (2000) Low dopamine D₂ receptor binding potential in social phobia. Am J Psychiatry 157:457–459PubMedCrossRef

Schneier FR, Martinez D, Abi-Dargham A et al (2008) Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings. Depress Anxiety 25:1–7PubMedCrossRef

Schneier FR, Abi-Dargham A, Martinez D et al (2009) Dopamine transporters, D(2) receptors, and dopamine release in generalized social anxiety disorder. Depress Anxiety 26:411–418PubMedCrossRef

Schutters SI, van Megan HJ, Westenberg HG (2005) Efficacy of Quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psychiatry 66:540–542PubMedCrossRef

Sheehan DV, Lecrubier Y, Sheehan KH et al (1998) The MINI-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33PubMed

Smith GS, Ma Y, Dhawan V et al (2009) Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with (11C)-raclopride and positron emission tomography. Synapse 63:1–6PubMedCrossRef

Stein DJ, Ipser J, van Balkom A (2004) Pharmacotherapy for social phobia. Cochrane Database Syst Rev 4:CD001206PubMed

Tiihonen J, Kuikka J, Bergstrom K et al (1997) Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 154:239–242PubMed

Van der Linden GJ, Stein DJ, Van Balkom AJ (2000) The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomised controlled trials. Int Clin Psychopharmacol 15(suppl 2):S15–S23PubMed

Van der Wee NJ, Van Veen JF, Stevens H et al (2008) Increased serotonin and dopamine transporter binding in psychotropic medication-naïve patients with generalised social anxiety disorder shown by ¹²³I-β-(4-iodophenyl)-tropane SPECT. J Nucl Med 49:757–763PubMedCrossRef

Vandenbergh DJ, Persico AM, Hawkins AL et al (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104–1106PubMedCrossRef

VanNess SH, Owens MJ, Kilts CD (2005) The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6:55PubMedCrossRef

Wichmann T, DeLong MR (1996) Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 6:751–758PubMedCrossRef

Title: Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram
Authors: J. M. Warwick
P. D. Carey
N. Cassimjee
C. Lochner
S. Hemmings
H. Moolman-Smook
E. Beetge
P. Dupont
D. J. Stein
Publication date: 01-06-2012
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 2/2012
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-012-9280-3

2024 ASCO Annual Meeting

Springer Medicine

Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

The spleen contributes to stroke induced neurodegeneration through interferon gamma signaling

Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats

Successful unrelated umbilical cord blood transplantation in Lesch-Nyhan syndrome

Activation of acetylcholinesterase after U-74389G administration in a porcine model of intracerebral hemorrhage

Mimicry between mitochondrial disorder and multiple sclerosis

Thyroid hormone’s role in regulating brain glucose metabolism and potentially modulating hippocampal cognitive processes